Using Doppler ultrasound resistive index to distinguish benign and malignant breast masses

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study records minimum, maximum, and average Doppler resistive index (RI) values from solid breast masses, adjacent healthy tissue, and the opposite breast, then calculates relative RI differences between mass and healthy tissue. Cases are classified by pathology into benign and malignant groups and threshold RI differences that separate these groups will be determined. In addition, vascular index measurements using Doppler Microvascular Flow imaging will be calculated for each mass to add microvascular information. The design is observational and excludes cystic or hypovascular masses and cases with mastitis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Those with solid breast masses
* Female patients
* Those with pathology results

Exclusion Criteria:

* Hypovascular masses
* Cystic breast masses
* Cases with mastitis

Where it's running

• Karamanoğlu Mehmetbey University, KEAH
  Karaman, Lütfen Seçiniz., Turkey (Türkiye) Recruiting

Study contacts

• Study coordinator: Ahmet Yeşildağ, Prof.Dr
• Email: ahmetysd@hotmail.com
• Phone: +905057728297

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pre-Treatment Breast DCE-MRI AI Model to Predict Benefit from Neoadjuvant Chemo in Locally Advanced Triple-Negative Breast Cancer

  This study tests an AI model using pre-treatment breast MRI to see if it can identify which locally advanced triple-negative breast cancer patients will benefit most from neoadjuvant chemotherapy.

  Recruiting Fujian Cancer Hospital · Fuzhou, Fujian and 4 other locations · NCT07880600

• Time‑restricted eating (8‑hour window) during chemotherapy for breast cancer: feasibility and acceptability

  This trial will test whether eating all daily food within an 8‑hour window is practical and acceptable for people starting chemotherapy for stage I–III breast cancer (and some stage IV with oncologist approval).

  Recruiting at 2 sites University of Illinois Chicago · Chicago, Illinois and 1 other locations · NCT07387445

• FYI on MRI: decision support to help high-risk Black and Latina women decide about screening breast MRI

  This project will test whether adding a decision aid to risk assessment and nurse referral helps high-risk Black and Latina women make informed choices about screening breast MRI.

  Recruiting Georgetown University · Washington D.C., District of Columbia · NCT06892275

• Treatment for locally advanced HER2-positive breast cancer using a combination of drugs

  This study is testing a new combination of drugs to see if it can help women with locally advanced HER2-positive breast cancer get better before surgery.

  Recruiting First Affiliated Hospital of Wenzhou Medical University · Wenzhou, Zhejiang · NCT06234137

• Comparing two types of breast radiation therapy after surgery

  This study is testing whether partial breast radiation or whole breast radiation works better for women with small, node-negative breast cancer after surgery.

  Recruiting at 30 sites Phase 3 Ontario Clinical Oncology Group (OCOG) · Darlinghurst, New South Wales and 30 other locations · NCT05417516

• Stereotactic radiotherapy for early breast cancer in elderly women

  This study is testing a non-surgical radiation treatment for women aged 75 and older with early breast cancer to see if it can effectively target their tumors.

  Recruiting University of Rome Tor Vergata · Rome, Rome · NCT05071105

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.